Indicated for type 2 diabetes mellitus to manage glycemic levels and support insulin response.
Mechanism of Action
Pioglitazone increases insulin sensitivity in peripheral tissues via PPAR-gamma activation. Metformin reduces hepatic glucose production and intestinal glucose absorption, together providing comprehensive glycemic control.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
12–24 hours
Contraindications
Congestive heart failure, Severe renal impairment, Metabolic acidosis, Active bladder cancer
Severe Adverse Events
Lactic acidosis, Congestive heart failure exacerbation, Bladder cancer — requires immediate medical attention
Common Side Effects
Headache, Diarrhea, Nausea
Uncommon Side Effects
Peripheral edema, Weight gain, Upper respiratory tract infection
Information related to Actoplus Met is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
